Hong Kong-listed Chinese biotech METiS TechBio has licensed global rights to its preclinical trispecific T-cell engager MTS-128 to Deerfield-backed Boulevard Bio, in a deal potentially worth more than ...

France’s Abivax today announced the pricing of its previously announced underwritten public offering of 6,400,000 American Depositary Shares (ADSs) each representing one ordinary share, 0.01 euro ...

AlzeCure Pharma has signed an out-licensing and collaboration agreement with Denmark’s privately held QuantumCell, granting ...

The Pharma Letter’s June M&A coverage showed that biopharma buyers remain prepared to pay heavily for late-stage or strategically useful assets, while also using smaller deals to fill technology and ...

French pharma Ipsen is continuing to expand its product portfolio via M&A deals, today announcing plans to acquire privately-owned Swiss biotech Memo Therapeutics.

BridgeBio Pharma today announced that it has entered into an agreement with funds managed by Sixth Street and funds managed by HealthCare Royalty, a business of KKR and, together with Sixth Street, ...

Swiss biopharmaceutical company Idorsia has appointed Roland Wandeler as chief executive officer, effective October 1, as it looks to build on a recent financial turnaround and accelerate growth ...

US clinical-stage biotech Beeline Medicines has announced the closing of a $126.3 million Series A extension, bringing its total Series A financing round to $426.3 million.

UK-based BioPhorum today announced the formation of the Synthetic Molecule Process Innovation Phorum, uniting an ecosystem of 20 leading organizations to urgently address the rapidly accelerating pace ...

Danish biotech company Muna Therapeutics has named Michel Detheux as chief executive as it prepares to move its lead ...

Privately-held US cell therapy company Orca Bio announced the US Food and Drug Administration (FDA) has approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq), ...